> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

Inimex Pharmaceuticals and SARomics Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration

| Print |
Monday, 13 December 2010 14:00 (UTC + 1)
SARomicsBS_Logo_small Inimex_Logo

Vancouver, BC, Canada and Lund, Sweden, December 13, 2010 / b3c newswire / – Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex’s Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.


The p62 ZZ domain was cloned, expressed, purified and crystallized by SARomics Biostructures in collaboration with their molecular biology partner Vectron Biosolutions in Trondheim, Norway. Excellent crystallographic data were obtained at the MAX-lab synchrotron in Lund, Sweden.


“We are very excited to be able to help Inimex Pharmaceuticals fully leverage the potential of IMX942 by revealing the molecular details of its interactions with its target protein”, says Dr. Derek Logan, Chief Scientific Officer of SARomics Biostructures AB.


About IMX942

IMX942 is the first of a new class of drugs known as Innate Defense Regulators (IDRs), which improve survival, ameliorate tissue damage and reduce bacterial infections through modulation of innate defenses. IMX942 is a small, proprietary, fully synthetic peptide that binds to the intracellular adaptor protein p62 and modifies the signaling network downstream of TLR, TNF, and IL-1 receptors. IMX942 acts on the final common pathways of pathogenesis, being effective against antibiotic resistant infections and controlling the outcome of disease caused by a broad spectrum of pathogens, by chemotherapy and by localized radiation.


About Inimex Pharmaceuticals - www.inimexpharma.com

Inimex Pharmaceuticals Inc. is a privately held biopharmaceutical company dedicated to the discovery and development of new medicines based on the selective modulation of the innate immune response. The Company’s first drug candidate, IMX942, has completed Phase 1 clinical studies in healthy volunteers and is in development for a number of indications, including control of disease in high-risk patients in the hospital setting. For more information, please visit www.inimexpharma.com.


About SARomics Biostructures AB - www.saromics.com

SARomics Biostructures is the leading Scandinavian provider of structural biology and in silico drug discovery services. The privately held company accelerates its customers’ drug discovery processes by providing contract R&D support in the areas of protein crystallization, protein structure determination, NMR spectroscopy and computational chemistry. SARomics Biostructures is equipped with state-of-the-art robotics for low volume high-throughput crystallization and X-ray diffraction experiments. Its strategic location close to the MAX-lab synchrotron radiation facility in Lund, Sweden provides instant access to beamlines for data collection enabling rapid project turnaround. For further general information please visit www.saromics.com.



Dr. Björn Walse

Director Sales & Marketing

SARomics Biostructures AB

Scheelevägen 22

SE-223 63 Lund

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

tel. +46 46 191276.